Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor

Molecular and Cellular Endocrinology

Volumn 399, Issue , 2015, Pages 330-335

  Harvey, Pamela Ann ^a   Leinwand, Leslie Anne ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiotoxicity; Genistein; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

DAIDZEIN; GENISTEIN; PHYTOESTROGEN; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; ANTINEOPLASTIC AGENT; CARDIOTOXIN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL ISOLATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY SOY SUPPLEMENTATION; DISEASE EXACERBATION; DRUG POTENTIATION; FOOD DRUG INTERACTION; HEART FUNCTION; HEART MUSCLE CELL; LETHALITY; MALE; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE CELL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; SOYBEAN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDIOTOXINS; INDOLES; MALE; MICE; MYOCYTES, CARDIAC; PHYTOESTROGENS; PROTEIN KINASE INHIBITORS; PYRROLES; SOYBEANS;

EID: 84909594497     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.10.011     Document Type: Article

References (40)

1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem 1987, 262:5592-5595.
2. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
3. deVere White R.W., Tsodikov A., Stapp E.C., Soares S.E., Fujii H., Hackman R.M. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr. Cancer 2010, 62:1036-1043.
4. Dang Z.C., Lowik C. Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol Metab 2005, 16:207-213.
5. Dubey R.K., Jackson E.K., Gillespie D.G., Zacharia L.C., Imthurn B., Keller P.J. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler. Thromb. Vasc. Biol 2000, 20:964-972.
6. El Touny L.H., Banerjee P.P. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009, 69:3695-3703.
7. Fontana L., Vinciguerra M., Longo V.D. Growth factors, nutrient signaling, and cardiovascular aging. Circ. Res 2012, 110:1139-1150.
8. Fryer R.M., Schultz J.E., Hsu A.K., Gross G.J. Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. Am. J. Physiol 1998, 275:H2009-H2015.
9. Haines C.D., Harvey P.A., Luczak E.D., Barthel K.K., Konhilas J.P., Watson P.A., et al. Estrogenic compounds are not always cardioprotective and can be lethal in males with genetic heart disease. Endocrinology 2012, 153:4470-4479.
10. Hasinoff B.B., Patel D., O'Hara K.A. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol 2008, 74:1722-1728.
11. Herbert J.M., Seban E., Maffrand J.P. Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun 1990, 171:189-195.
12. Hool L.C., Middleton L.M., Harvey R.D. Genistein increases the sensitivity of cardiac ion channels to beta-adrenergic receptor stimulation. Circ. Res 1998, 83:33-42.
13. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006, 368:1303-1304.
14. Jones S.M., Kazlauskas A. Growth factor-dependent signaling and cell cycle progression. Chem. Rev 2001, 101:2413-2423.
15. Joshi M.S., Tong L., Cook A.C., Schanbacher B.L., Huang H., Han B., et al. Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival. Cardiovasc. Pathol 2012, 21:428-435.
16. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med 2006, 12:908-916.
17. Lankheet N.A., Blank C.U., Mallo H., Adriaansz S., Rosing H., Schellens J.H., et al. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J. Anal. Toxicol 2011, 35:558-565.
18. Liew R., Williams J.K., Collins P., MacLeod K.T. Soy-derived isoflavones exert opposing actions on Guinea pig ventricular myocytes. J. Pharmacol. Exp. Ther 2003, 304:985-993.
19. Lin A.H., Leung G.P., Leung S.W., Vanhoutte P.M., Man R.Y. Genistein enhances relaxation of the spontaneously hypertensive rat aorta by transactivation of epidermal growth factor receptor following binding to membrane estrogen receptors-alpha and activation of a G protein-coupled, endothelial nitric oxide synthase-dependent pathway. Pharmacol. Res 2011, 63:181-189.
20. Lissin L.W., Cooke J.P. Phytoestrogens and cardiovascular health. J. Am. Coll. Cardiol 2000, 35:1403-1410.
21. Maass A.H., Buvoli M. Cardiomyocyte preparation, culture, and gene transfer. Methods Mol. Biol 2007, 366:321-330.
22. Moon W., Balasubramanian S.K., Rimal A. Perceived health benefits and soy consumption behavior: two-stage decision model approach. J. Agric. Resour. Econ 2005, 30:315-332.
23. Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., Yu, M, Ruhl, J., Tatalovich, Z.,Mariotto, A., Lewis, D.R., Chen, HS, Feuer, E.J., Cronin, K.A. (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975_2011/.
24. Okubo S., Tanabe Y., Takeda K., Kitayama M., Kanemitsu S., Kukreja R.C., et al. Pretreatment with tyrosine kinase inhibitor attenuates the reduction of apoptosis 24 h after ischemic preconditioning. Jpn J. Physiol 2004, 54:143-151.
25. Pfister O., Lorenz V., Oikonomopoulos A., Xu L., Hauselmann S.P., Mbah C., et al. FLT3 activation improves post-myocardial infarction remodeling involving a cytoprotective effect on cardiomyocytes. J. Am. Coll. Cardiol 2014, 63:1011-1019.
26. Pfizer 2013 Sutent (sunitinib malate) labeling. New York, NY 10017.
27. Piell K.M., Qipshidze Kelm N., Caroway M.P., Aman M., Cole M.P. Nitrite treatment rescues cardiac dysfunction in aged mice treated with conjugated linoleic acid. Free Radic. Biol. Med 2014, 72:66-75.
28. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med 2011, 364:501-513.
29. Sacks F.M., Lichtenstein A., Van Horn L., Harris W., Kris-Etherton P., Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006, 113:1034-1044.
30. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol 1995, 19:183-232.
31. Sarkar F.H., Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006, 66:3347-3350.
32. Si H., Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J. Nutr 2008, 138:297-304.
33. Stadler W.M., Szmulewitz R.Z. Sunitinib - a new standard of care for metastatic renal cell carcinoma. Nat. Clin. Pract. Oncol 2007, 4:458-459.
34. Stauffer B.L., Konhilas J.P., Luczak E.D., Leinwand L.A. Soy diet worsens heart disease in mice. J. Clin. Invest 2006, 116:209-216.
35. Tsai H.H., Lin H.W., Simon Pickard A., Tsai H.Y., Mahady G.B. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int. J. Clin. Pract 2012, 66:1056-1078.
36. Ueda Y., Igishi T., Hashimoto K., Suyama H., Araki K., Sumikawa T., et al. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. Int. J. Oncol 2009, 34:689-696.
37. Xu X., Cang H., Li C., Zhao Z.K., Li H. Quartz crystal microbalance sensor array for the detection of volatile organic compounds. Talanta 2009, 78:711-716.
38. Zava D.T., Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr. Cancer 1997, 27:31-40.
39. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
40. Zhang J., Cao R., Zhang Y., Jia T., Cao Y., Wahlberg E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 2009, 23:153-163.